Efung Capital Honored on Rongzhong 2025 Annual China Equity Investment Ranking | Fenix Glory

Date： 2026-01-14

On January 14, 2026, the Rongzhong 2025 Annual China Equity Investment Ranking was officially unveiled. Fenix Capital was named to the "Rongzhong 2025 Annual Top 100 Chinese Venture Capital Institutions," and Efung Capital CEO Zhu Pai was recognized as a "Rongzhong 2025 Outstanding Chinese Investor."

Leveraging its proprietary database, BridgeData, combined with questionnaire collection, research interviews, and comprehensive data validation, Rongzhong Research conducted an overall assessment in consideration of market and industry development trends.

Looking ahead, Efung Capital will continue to anchor itself in the biopharmaceutical sector, using capital empowerment as a lever, industrial collaboration as a bridge, and long-term partnership as a guiding philosophy. The firm is committed to driving the transformation and commercialization of technological innovations, injecting strong momentum into the high-quality development of the biopharmaceutical industry.

Previous：Efung Capital's Portfolio Companies MakeNext：Anchoring Innovation, Winning the Future

Related News / Recommended news More

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

2026 - 03 - 24

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

2026 - 03 - 25

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

2026 - 03 - 05

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...